Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
:1877
Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$26.00
â–Ľ(-1.44% Downside)
Action:ReiteratedDate:04/02/26
The score is held back primarily by weak financial performance—ongoing losses, volatile revenue, and significant cash burn with rising debt. Technicals provide partial support due to strong momentum above key moving averages, but overbought signals add risk. Valuation remains constrained by unprofitability and the lack of a dividend yield.
Positive Factors
Integrated value chain
Junshi’s integrated model — discovery through commercialization — creates durable operational advantages: tighter clinical-to-commercial feedback loops, ownership of manufacturing and launch execution, and multiple potential revenue levers (sales, licensing, contract income). This reduces reliance on single partners and supports sustained product franchise building over the next several quarters.
Negative Factors
Persistent negative cash generation
Consistent negative operating and free cash flow is a durable constraint: ongoing cash burn forces reliance on external funding, increasing dilution or debt financing risk. This limits the company’s ability to self-fund late-stage trials, marketing rollouts, or manufacturing scale-ups, raising execution and financing risks over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated value chain
Junshi’s integrated model — discovery through commercialization — creates durable operational advantages: tighter clinical-to-commercial feedback loops, ownership of manufacturing and launch execution, and multiple potential revenue levers (sales, licensing, contract income). This reduces reliance on single partners and supports sustained product franchise building over the next several quarters.
Read all positive factors
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$40.58B
Dividend YieldN/A
Average Volume (3M)7.63M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth38.56%
EPS Growth48.26%
CountryHK
Employees2,578
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$33.35Price Target Upside26.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.52
Revenue Forecast (FY)HK$3.30B
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in t...
How the Company Makes Money
Junshi Biosciences generates revenue primarily through (1) product sales of its commercialized drugs, where income is recognized from selling medicines to distributors, hospitals, pharmacies, and other healthcare channels (depending on the market ...
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.43B | 1.95B | 1.50B | 1.45B | 4.02B |
| Gross Profit | 1.76B | 1.54B | 835.26M | 927.21M | 2.77B |
| EBITDA | -599.38M | -935.50M | -2.16B | -2.52B | -476.32M |
| Net Income | -851.76M | -1.28B | -2.28B | -2.39B | -718.56M |
Balance Sheet | |||||
| Total Assets | 12.39B | 10.80B | 11.36B | 12.58B | 11.05B |
| Cash, Cash Equivalents and Short-Term Investments | 3.22B | 2.93B | 3.78B | 6.00B | 3.50B |
| Total Debt | 4.14B | 2.93B | 1.79B | 1.32B | 628.20M |
| Total Liabilities | 6.16B | 4.85B | 4.02B | 2.78B | 2.72B |
| Stockholders Equity | 6.03B | 5.86B | 7.17B | 9.50B | 7.96B |
Cash Flow | |||||
| Free Cash Flow | -1.21B | -2.12B | -2.85B | -2.17B | -1.53B |
| Operating Cash Flow | -465.77M | -1.43B | -2.01B | -1.78B | -641.90M |
| Investing Cash Flow | -1.58B | -892.78M | -892.42M | -467.62M | -1.88B |
| Financing Cash Flow | 2.17B | 1.02B | 681.04M | 4.64B | 2.67B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Positive
26.38
Price Trends
21.38
Positive
22.68
Positive
25.40
Positive
Market Momentum
1.02
Negative
75.36
Negative
90.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1877, the sentiment is Positive. The current price of 26.38 is above the 20-day moving average (MA) of 21.52, above the 50-day MA of 21.38, and above the 200-day MA of 25.40, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 75.36 is Negative, neither overbought nor oversold. The STOCH value of 90.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1877.
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
65 Neutral | HK$83.77B | 51.47 | 32.32% | ― | 46.14% | 39.56% | |
53 Neutral | HK$8.81B | -76.25 | -6.26% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$17.86B | -10.93 | -22.81% | ― | 23.87% | 30.08% | |
44 Neutral | HK$19.28B | -6.78 | -123.74% | ― | -56.94% | -190.36% |
* Healthcare Sector Average
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
HK:9688
Zai Lab Ltd
15.78
-5.82
-26.94%
HK:9966
Alphamab Oncology
9.04
3.11
52.45%
HK:9995
RemeGen Co. Ltd. Class H
115.20
93.60
433.33%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
49.85
186.36%
HK:6855
Ascentage Pharma Group International
52.05
18.40
54.68%
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase
Mar 31, 2026
Shanghai Junshi Biosciences has disclosed that its chairman, controlling shareholder and actual controller, Xiong Jun, has completed a planned increase in his holdings of both A shares and H shares of the company. The plan, launched on 12 April 20...
Shanghai Junshi Biosciences Schedules 2025 Results Briefing for Investor Q&A
Mar 20, 2026
Shanghai Junshi Biosciences Co., Ltd. has announced plans to hold its 2025 annual results briefing, following the disclosure of its 2025 annual report on the Shanghai Stock Exchange website on 14 March 2026. The online briefing will be held via th...
Junshi Biosciences Chairman Continues Shareholding Increase Plan
Mar 16, 2026
Shanghai Junshi Biosciences announced the latest progress of a previously disclosed plan by chairman and controlling shareholder Xiong Jun to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑mo...
Junshi Biosciences Board Approves 2025 Work Report and Highlights Governance Actions
Mar 13, 2026
Shanghai Junshi Biosciences Co., Ltd. has reported that its seventeenth meeting of the fourth session of the board of directors was duly convened on 13 March 2026, with all 14 eligible directors in attendance and procedures confirmed as compliant ...
Shanghai Junshi Biosciences Details Board and Committee Structure
Mar 13, 2026
Shanghai Junshi Biosciences Co., Ltd. has announced the current composition of its board of directors, which includes a mix of executive, non-executive and independent non-executive directors, led by chairman and legal representative Xiong Jun. Th...
Shanghai Junshi Biosciences Sets Terms for New Strategic and ESG Board Committee
Mar 13, 2026
Shanghai Junshi Biosciences Co., Ltd. has established a Strategic and ESG Committee under its board of directors, formalizing the committee’s terms of reference to guide its structure and operations. The document outlines the committee’...
Junshi Biosciences Adds ESG Focus and Revamps Pay Policies
Mar 13, 2026
Shanghai Junshi Biosciences has upgraded its board-level strategic committee into a Strategic and ESG Committee, expanding its remit to cover environmental, social and governance issues alongside long-term strategy and major investments. The move ...
Shanghai Junshi Biosciences Lifts Revenue and Narrows Loss as Immuno-Oncology Pipeline Advances
Mar 13, 2026
Shanghai Junshi Biosciences reported a 28% rise in 2025 revenue to about RMB2.5 billion, driven mainly by a 38% surge in domestic sales of its core PD-1 antibody TUOYI, while RD spending rose 9% to RMB1.38 billion as the company pushed more compet...
Junshi Biosciences Details Use and Return of Idle Fundraising Proceeds for Liquidity
Mar 12, 2026
Shanghai Junshi Biosciences has disclosed that it previously obtained board approval to use up to RMB2 billion of idle fundraising proceeds to temporarily supplement working capital for up to 12 months. The funds were restricted to business expans...
Junshi Biosciences Chairman Continues Incremental Share Purchase Plan
Mar 10, 2026
Shanghai Junshi Biosciences has disclosed progress on a previously announced plan by chairman and controlling shareholder Xiong Jun to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑month per...
Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China
Mar 9, 2026
Shanghai Junshi Biosciences has received acceptance from China’s National Medical Products Administration for new drug applications covering 12 tumor-related indications of its toripalimab subcutaneous injection, JS001sc. The formulation is ...
Shanghai Junshi Biosciences Sets March 2026 Board Meeting to Approve 2025 Results
Mar 2, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for 13 March 2026 to review and approve the group’s final results for the financial year ended 31 December 2025. The board will also consider whether to recommend a final di...
Junshi Biosciences Narrows 2025 Loss as Revenue Climbs Nearly 30%
Feb 27, 2026
Shanghai Junshi Biosciences Co., Ltd., a China-based biopharmaceutical developer of innovative antibody drugs and other advanced therapies, operates in the competitive global healthcare market with a focus on major disease areas. The company is li...
Junshi Biosciences Chairman Progresses RMB100 Million Shareholding Increase Plan
Feb 10, 2026
Shanghai Junshi Biosciences has disclosed an update on a previously announced plan by chairman and controlling shareholder Xiong Jun to increase his holdings in both A shares and H shares. Xiong plans to invest at least RMB100 million in total, wi...
Junshi Biosciences Forecasts Strong 2025 Revenue Growth and Narrowing Loss on TUOYI Sales
Jan 30, 2026
Shanghai Junshi Biosciences has issued a preliminary 2025 results forecast indicating strong top-line growth driven by increased sales of commercialized products, particularly domestic revenue from its flagship immunotherapy TUOYI. Operating reven...
Shanghai Junshi Biosciences Raises RMB1 Billion via Technology Innovation Bonds
Jan 26, 2026
Shanghai Junshi Biosciences has completed the issuance of its 2026 first tranche of technology innovation bonds, raising RMB1 billion with a 3+2-year term maturing in January 2031 at an interest rate of 2.70%. The successful bond issuance strength...
Junshi Biosciences Chairman Starts Shareholding Increase Plan
Jan 9, 2026
Shanghai Junshi Biosciences announced that its chairman, controlling shareholder and actual controller, Xiong Jun, has begun implementing a previously disclosed plan to increase his holdings in the company’s A and H shares by at least RMB100...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.